Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area

Acta Haematologica

Volumn 118, Issue 4, 2008, Pages 219-221

  Park, Seh Jong ^a   Choi, In Keun ^a,b   Seo, Hee Yun ^a   Sung, Hwa Jung ^a   Park, Kyong Hwa ^a   Kim, Seok Jin ^a   Oh, Sang Cheul ^a   Seo, Jae Hong ^a   Choi, Chul Won ^a   Kim, Byung Soo ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; BODY SURFACE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; LEUKOCYTE COUNT; LOADING DRUG DOSE; MALE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEUTROPENIA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 38749103513     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111777     Document Type: Article

References (6)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, Chiba S, Hirai H, Tauchi T, Urabe A, Takahashi M, Ohnishi K, Yokozawa T, Emi N, Hirano M, Shimazaki C, Nakao S, Kawai Y, Fujimoto M, Taguchi H, Jinnai I, Ohno R: Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol 2004;80:261-266.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
4. Raanani P, Ben-Bassat I, Gan S, Trakhtenbrot L, Mark Z, Ashur-Fabian O, Itskovich S, Brok-Simoni F, Rechavi G, Amariglio N, Nagler A: Assessment of the response to imatinib in chronic myeloid leukemia patients - comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol 2004;73:243-250.
5. Horikoshi A, Takei K, Sawada S: Effects of lower dose of imatinib to CML patients. Leuk Res 2003;27:1167.
6. Horikoshi A, Takei K, Sawada S: Relationship between the daily dose of imatinib per square meter, and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res 2007;31:574-575.